DRW Securities LLC Buys Shares of 109,504 Hims & Hers Health, Inc. (NYSE:HIMS)

DRW Securities LLC acquired a new stake in Hims & Hers Health, Inc. (NYSE:HIMS) during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 109,504 shares of the company’s stock, valued at approximately $2,017,000.

Several other institutional investors and hedge funds have also recently bought and sold shares of HIMS. Alpha DNA Investment Management LLC acquired a new position in Hims & Hers Health during the 3rd quarter worth about $552,000. Charles Schwab Investment Management Inc. increased its stake in Hims & Hers Health by 15.1% during the third quarter. Charles Schwab Investment Management Inc. now owns 1,667,422 shares of the company’s stock worth $30,714,000 after purchasing an additional 218,566 shares during the period. Massachusetts Financial Services Co. MA purchased a new stake in shares of Hims & Hers Health during the third quarter worth $2,395,000. Intech Investment Management LLC acquired a new stake in shares of Hims & Hers Health in the 3rd quarter valued at $1,064,000. Finally, Quest Partners LLC raised its stake in Hims & Hers Health by 22.6% in the third quarter. Quest Partners LLC now owns 4,373 shares of the company’s stock valued at $81,000 after buying an additional 807 shares in the last quarter. 63.52% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In related news, Director Christiane Pendarvis sold 7,000 shares of the business’s stock in a transaction that occurred on Tuesday, August 27th. The shares were sold at an average price of $15.15, for a total value of $106,050.00. Following the completion of the sale, the director now directly owns 23,917 shares in the company, valued at approximately $362,342.55. The trade was a 22.64 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Oluyemi Okupe sold 269,739 shares of Hims & Hers Health stock in a transaction on Monday, October 14th. The shares were sold at an average price of $20.31, for a total transaction of $5,478,399.09. Following the completion of the transaction, the chief financial officer now owns 145,763 shares in the company, valued at approximately $2,960,446.53. This trade represents a 64.92 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 1,056,183 shares of company stock valued at $21,501,682 in the last quarter. 17.71% of the stock is currently owned by company insiders.

Hims & Hers Health Stock Performance

HIMS stock opened at $25.33 on Monday. The stock’s 50 day moving average price is $20.55 and its 200 day moving average price is $19.31. The firm has a market cap of $5.53 billion, a P/E ratio of 57.57 and a beta of 1.06. Hims & Hers Health, Inc. has a 1 year low of $8.02 and a 1 year high of $30.44.

Hims & Hers Health (NYSE:HIMS) last posted its quarterly earnings data on Monday, November 4th. The company reported $0.32 EPS for the quarter, beating analysts’ consensus estimates of $0.06 by $0.26. The business had revenue of $401.56 million for the quarter, compared to analyst estimates of $382.20 million. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. The business’s revenue for the quarter was up 77.1% compared to the same quarter last year. During the same quarter last year, the company earned ($0.04) earnings per share. On average, research analysts predict that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current year.

Analyst Ratings Changes

Several equities analysts have commented on the stock. Piper Sandler reiterated a “neutral” rating and issued a $21.00 price target (up from $18.00) on shares of Hims & Hers Health in a research note on Tuesday, November 5th. Bank of America lowered Hims & Hers Health from a “buy” rating to an “underperform” rating and dropped their price objective for the stock from $32.00 to $18.00 in a report on Thursday, November 14th. Needham & Company LLC started coverage on Hims & Hers Health in a research note on Thursday, August 22nd. They set a “buy” rating and a $24.00 price target on the stock. Deutsche Bank Aktiengesellschaft boosted their price objective on Hims & Hers Health from $23.00 to $27.00 and gave the company a “hold” rating in a research note on Wednesday, November 6th. Finally, Imperial Capital lowered shares of Hims & Hers Health from an “outperform” rating to an “in-line” rating in a research report on Friday, August 9th. One analyst has rated the stock with a sell rating, eight have assigned a hold rating and seven have given a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $20.71.

Hims & Hers Health Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.